Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| size | 100ug |
|---|---|
| Brand | ProteoGenix |
| Product type | Recombinant Proteins |
| Host Species | Escherichia coli (E. coli) |
| Applications | Elisa, WB |
| Product name | Human CD20/MS4A1 recombinant protein |
|---|---|
| Uniprot ID | P11836 |
| Origin species | Homo sapiens (Human) |
| Expression system | Prokaryotic expression |
| Molecular weight | 19.58 kDa |
| Protein delivered with Tag? | N-Terminal His & N-Terminal Trx Tags |
| Purity estimated | >85% by SDS-PAGE |
| Buffer | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| Delivery condition | Dry Ice |
| Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
| Brand | ProteoGenix |
| Host species | Escherichia coli (E.coli) |
| Fragment Type | Ile143-Ser188 |
| Aliases /Synonyms | B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20 |
| Reference | PX-P6274 |
| Note | For research use only |
The human CD20/MS4A1 recombinant protein is a type I membrane protein composed of a single extracellular loop, a single transmembrane domain, and a cytoplasmic tail. It is expressed on the surface of B-cells and is involved in B-cell activation and proliferation.
The activity of the human CD20/MS4A1 recombinant protein is mediated by its interaction with other proteins, such as CD19 and CD21, which are involved in B-cell activation and proliferation. The CD20/MS4A1 protein is also involved in the regulation of B-cell differentiation and maturation.
The human CD20/MS4A1 recombinant protein is a promising target for the development of antibody-drug conjugates for the treatment of B-cell malignancies. Antibodies targeting the CD20/MS4A1 protein have been successfully used in clinical trials, demonstrating their potential as an effective treatment for various B-cell malignancies.
Immobilized Human CD20/MS4A1 recombinant protein (cat. No.PX-P6274) at 0.5µg/mL (100µL/well) can bind to Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb (cat. No.PX-TA1162) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.